The Zhitong Finance App learned that Morgan Stanley said that Johnson & Johnson (JNJ.US) released several major clinical data at the recent American Society of Hematology (ASH) annual meeting. Among them, Tecvayli and Darzalex combination therapy (Tec-Dara) had outstanding performance in the phase III clinical trial (MajesTec-3) of second-line treatment of relapsed/refractory multiple myeloma (RRMM), which is significantly superior to existing standard treatments. It is expected to promote the expansion of this combination therapy to more advanced treatment. At the same time, the new CAR-T therapy developed by Johnson & Johnson also showed potential competitiveness. Currently, Damo maintains Johnson & Johnson's “hold and wait” rating, and the target price is 190 US dollars.

The Zhitong Finance App learned that Morgan Stanley said that Johnson & Johnson (JNJ.US) released several major clinical data at the recent American Society of Hematology (ASH) annual meeting. Among them, Tecvayli and Darzalex combination therapy (Tec-Dara) had outstanding performance in the phase III clinical trial (MajesTec-3) of second-line treatment of relapsed/refractory multiple myeloma (RRMM), which is significantly superior to existing standard treatments. It is expected to promote the expansion of this combination therapy to more advanced treatment. At the same time, the new CAR-T therapy developed by Johnson & Johnson also showed potential competitiveness. Currently, Damo maintains Johnson & Johnson's “hold and wait” rating, and the target price is 190 US dollars.